RTW Biotech Opportunities (LON:RTW) Reaches New 12-Month High – Still a Buy?

Shares of RTW Biotech Opportunities (LON:RTWGet Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 2.49 and last traded at GBX 2.45, with a volume of 98661 shares trading hands. The stock had previously closed at GBX 2.48.

RTW Biotech Opportunities Trading Down 0.8%

The company has a quick ratio of 0.81, a current ratio of 0.15 and a debt-to-equity ratio of 20.05. The firm has a 50 day moving average price of GBX 2.34 and a 200 day moving average price of GBX 2.19. The stock has a market capitalization of £7.97 million, a PE ratio of 0.04 and a beta of 0.76.

About RTW Biotech Opportunities

(Get Free Report)

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Bio invests in companies developing next-generation therapies and technologies that can significantly improve patients’ lives. RTW Bio is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

See Also

Receive News & Ratings for RTW Biotech Opportunities Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTW Biotech Opportunities and related companies with MarketBeat.com's FREE daily email newsletter.